Outsourcing in Clinical Trials Nordics 201417-18 September 2014, Copenhagen, Denmark
With healthcare innovation and growth being considered a top priority for the Nordic region, clinical trials are regarded as a key aspect of delivery innovation, with governments incentivising and rewarding such efforts. One of the key considerations for the Nordics is the need for collaboration. Furthermore, with the increased rewards for innovation, the industry is looking to increase R&D activity, which in turn means there will be considerable development within clinical trials. Against this backdrop, OCT Nordics will allow companies from within this Nordic-specific hub to come together and discuss proven strategies to improve and create partnerships within clinical trials and medical devices.
Alongside the biopharmaceutical outsourcing sessions, we will also include unique medical device-specific sessions in a separate stream covering: medical device outsourcing, patient recruitment and new regulations (e.g. MDD). This year’s event will have more of an operational focus and bring together senior industry representatives to discuss the latest challenges within clinical outsourcing and medical device-related challenges such as: improved vendor communication strategies, vendor sourcing/selection, budgeting and contracting, oversight and management, patient recruitment, risk-based monitoring and feasibility plans.
Outsourcing in Clinical Trials Nordics 2014 promises to be a highly engaging meeting and will present a unique platform for discussion alongside thought-sharing on innovative strategies within outsourcing models in this ever-growing region.
Whether you are a senior professional in a global pharmaceutical company or a smaller company looking to expand, access to insight and knowledge about the latest pharmaceutical trends is vital.
The Outsourcing Clinical Trial series is growing every year. View the full list of upcoming events to make sure you don’t miss any news. The list of websites will be updated as soon as new events are live so check back regularly
Primary delegates for this event are those with responsibility for clinical outsourcing in biotech and pharma companies within the Nordic region.
We are always happy to see photos taken at our events! If you have any you would like to submit, please email firstname.lastname@example.org The Arena Team
Testimonials from other events in our Outsourcing in Clinical Trials Series
Outsourcing in Clinical Trials Nordics boasts a fantastic exhibition of clinical service providers and industry specialists. Our exhibition area is already filling up due to the fantastic launch event which took place this year. If you have a service or solution you would like to promote at this event, please use the details below to make contact with our commercial team.
Belgium-based biopharmaceutical firm UCB has reported positive topline results from the latest Phase III trial of brivaracetam, as adjunctive treatment in adult focal epilepsy patients with partial-onset seizures.
AstraZeneca's biologics research and development arm MedImmune has entered into a clinical trial collaboration with Advaxis, a US-based biotechnology firm that develops cancer immunotherapies.
US-based Dipexium Pharmaceuticals has started patient enrolment in the second of two pivotal Phase III clinical trials for its new drug aimed at treating diabetic patients with foot ulcers.
US-based biopharmaceutical firm Genocea Biosciences has initiated a Phase II dose optimisation trial for GEN-003, its immunotherapy candidate for treatment of herpes simplex-type 2 (HSV-2).
Bayer HealthCare and Regeneron Pharmaceuticals have reported positive results from the Phase III VIVID-DME trial of Eylea (aflibercept) injection for treatment of diabetic macular edema (DME).
Genmab partner Janssen Biotech is planning to initiate a new Phase III trial of daratumumab to treat patients with multiple myeloma in the fourth quarter of 2014.